Mark Purcell
Stock Analyst at Morgan Stanley
(1.81)
# 1,871
Out of 4,479 analysts
5
Total ratings
100%
Success rate
27.59%
Average return
Main Sectors:
Top Industries:
5 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVS Novartis AG | Initiates: Equal-Weight | $114 | $106.44 | +7.10% | 1 | Jan 23, 2024 | |
| SNY Sanofi | Initiates: Equal-Weight | $55 | $48.54 | +13.31% | 1 | Jan 23, 2024 | |
| GSK GSK | Initiates: Equal-Weight | $44 | $38.21 | +15.15% | 1 | Jan 23, 2024 | |
| AZN AstraZeneca | Initiates: Overweight | $85 | $76.99 | +10.40% | 1 | Jan 23, 2024 | |
| NVO Novo Nordisk | Initiates: Overweight | $120 | $142.98 | -16.07% | 1 | Jan 23, 2024 |
Novartis AG
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $114
Current: $106.44
Upside: +7.10%
Sanofi
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $55
Current: $48.54
Upside: +13.31%
GSK
Jan 23, 2024
Initiates: Equal-Weight
Price Target: $44
Current: $38.21
Upside: +15.15%
AstraZeneca
Jan 23, 2024
Initiates: Overweight
Price Target: $85
Current: $76.99
Upside: +10.40%
Novo Nordisk
Jan 23, 2024
Initiates: Overweight
Price Target: $120
Current: $142.98
Upside: -16.07%